Assessment Methods and Endpoints for Rapid-Acting Antidepressants-RAADs
Chairs: Mark Opler, PhD; Elizabeth Ballard, PhD
Most Recent Activity: Working Group Session, 7 September 2019, AC Bella Sky Hotel, Copenhagen, Denmark (Chairs: Elizabeth Ballard/Christian Yavorsky)
Group reviewed results of survey of clinicians assessing rapid acting ADs and followed up on items from 15th Annual meeting (see summary below).
(Detailed 2019 Autumn Conference Agenda – Includes Joint Day with ECNP)
Inaugural Working Group Session – 15th Annual Scientific Meeting-view summary – 19 February 2019, Washington DC
This working group will be focused on evaluating the validity and reliability of current and prospective future methods of assessment of efficacy, effectiveness of the “next wave” of treatments in mood disorders, utilizing the rapid acting antidepressants (RAADs) as a model. Do the instruments developed to evaluate the efficacy of older generations of treatments (e.g. MAOIs, TCAs, SSRIs) meet the needs of this new class of treatments? How well do they capture (a) speed of effect, (b) phenomenology, (c) patient experience, and (d) meaningful change? The inaugural working group meeting will take place at the 15th Annual Scientific meeting (19-21 February 2019) with a focus on developing and refining applicable domains to help evaluate the utility of different endpoints/instruments for this new class of treatments. Strengths and weakness of standard and novel assessment methods will be compiled with the goal of holding a session to present current evidence on this topic at a future ISCTM meeting.